medRxiv preprint doi: https://doi.org/10.1101/2020.07.24.20161547; this version posted July 27, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

1

Population Data-Driven Formulation of a
COVID-19 Therapeutic
Heather R. Campbell‚Äãa‚Äã, Regan Cecil‚Äãb‚Äã, Robert A. Lodder‚Äãa‚Äã,*
a‚Äã

Department of Pharmaceutical Sciences, University of Kentucky, Lexington, KY, USA
‚Äãb‚ÄãDepartment of Biology, University of Kentucky, Lexington, KY, USA
*Author to whom correspondence should be addressed. Email: ‚ÄãLodder@g.uky.edu

Abstract
This study is designed to utilize computer modeling of the US population through NHANES to
reduce the need for preclinical formulation and toxicology studies of an Ebola anti-viral
(BSN389) being repurposed for COVID-19, and to thereby speed the candidate therapeutic to
the clinic.

Introduction
Coronavirus disease of 2019, or COVID-19, is one of six identified coronavirus types to cause
disease in humans (Repici et al., 2020). The disease is caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) and was first identified in patients in Wuhan, China
(Repici et al., 2020). Major symptoms include fever, cough, shortness of breath, fatigue, new
loss of taste and smell, sore throat, congestion or runny nose, nausea or vomiting as well as
diarrhea (Repici et al., 2020; Tina, Saey, 2020a). Over half of patients infected report difficulty
breathing, with some reported cases of acute respiratory distress syndrome (Repici et al., 2020;
Wu, 2020). COVID-19 is known to be transmitted from person to person through
virus-containing droplets that may remain in the air or on surfaces for extended amounts of time
(Ghose, 2020; Tina, Saey, 2020b). The exact length of time the virus can survive in the air or on
a given surface seems to be highly dependent on the surface itself (Volkin, 2020). Regardless,
COVID-19 is thought to be particularly transmittable due to ridged Spike (S) proteins it contains
(Saplakoglu, 2020). These S proteins have been found to bind well to the
angiotensin-converting enzyme 2 (ACE2) found on the human cell surface, thereby serving as
an entry point for the virus (Balfour, 2020; Gray, 2020). The virus can spread asymptomatically
and has been predicted to infect millions of people, with some experts predicting up to 70% of
the US population will have been infected by August 2021 (Woodward and Miller, Medaris,
2020).
With millions expected to be infected, it is critical to ensure proper testing and diagnosis of
COVID-19 to maintain some control of infections. Currently, two major types of tests are being

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2020.07.24.20161547; this version posted July 27, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

2
utilized to identify COVID-19, molecular tests and serological tests. The following two sections
provide descriptions of each type.

Molecular testing techniques
Molecular based testing for COVID-19 aims to detect genetic material from SARS-CoV-2.
Although different types of molecular testing exist, they all tend to follow the process of first
detecting the RNA material, then making copies of the material until an output measurement is
produced if the RNA material was present (Kobokovich et al., 2020).
Laboratory Corporation of America was the first of the large national clinical laboratories in the
USA to offer a SARS-CoV-2 nucleic acid test (Haskins, 2020). This test utilizes polymerase
chain reaction (PCR) technology to detect the virus via nasopharyngeal (NP) or oropharyngeal
(OP) aspirates and washes, NP or OP swabs, and bronchoalveolar lavage (Haskins, 2020).
RealTime, a different molecular COVID-19 test manufactured by Abbott, also utilizes PCR
technology. However, these PCR tests can be time-consuming to perform, so to address this
slowness issue, Abbott released ID Now, the first 5-minute test that utilizes isothermal nucleic
acid amplification technology to speed up the process (Billingsley, 2020; Koval et al., 2020).
However, the accuracy of the ID Now has been questioned (Spaulding, 2020). In addition to
these authorized tests, multiple companies such as EverlyWell and OraSure have also
developed take-home test/collection kits, with LabCorps Pixel being the first to gain FDA
authorization (Hale, 2020; Koval et al., 2020; Spaulding and Mueller, 2020).

Serological testing techniques
Serological COVID-19 testing aims to identify individuals' exposure to the virus based on their
immune responses (Kobokovich et al., 2020b). Unlike molecular testing, serological testing,
specifically antibody testing, has the capability of identifying individuals who were previously
infected, which may provide invaluable insight for COVID-19 related tracking and research (Bai,
2020; Billingsley, 2020; Cohut and Godfrey, 2020; Covid-, 2020; Johnson, 2020; Kobokovich et
al., 2020b; Wu and Morrow, 2020). Many antibody tests have already obtained emergency use
authorization (EUA) from the FDA, such as Cellex‚Äôs Cellex qSARS-CoV-2 IgG/IgM rapid test,
which was first the antibody test to be authorized (Hale, 2020c). Additional antibody tests that
have EUA include Abbott‚Äôs Alinity I and Architect SARS-CoV-2 IgG tests, Autobio‚Äôs
Anti-SARS-CoV-2 rapid test, Bio-Rad Laboratories Platelia SARS-CoV-2 Total Ab, Chembio
Diagnostic systems‚Äô DPP Covid-19 IgM/IgG test and more (Colchester and Roland, 2020; FDA,
2020; Fernandez, 2020; Hale, 2020d). The current list of EUAs from FDA is available at
https://www.fda.gov/medical-devices/emergency-use-authorizations-medical-devices/coronaviru
s-disease-2019-covid-19-emergency-use-authorizations-medical-devices‚Äã.

medRxiv preprint doi: https://doi.org/10.1101/2020.07.24.20161547; this version posted July 27, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

3
Numerous research efforts have been initiated to improve serological testing, such as the
suggested serological assay for detecting SARS-CoV-2 seroconversion proposed by Amanant
and colleagues (Amanat et al., 2020). It should be noted that antibody testing is not meant to
diagnose active COVID-19 and can lack specificity, raising questions regarding its reliability
(Cairns, 2020; Hale, 2020e; McKinney, 2020; Patel, 2020). These two aspects, along with the
difficulty of scaling PCR testing among other factors, prompted the FDA to authorize a new
category of testing based on antigens (McKinney, 2020; Patel, 2020). These antigen tests aim
to identify the virus by detecting fragments of proteins found on or within the virus, and provide
high specificity for COVID-19. However, these tests are not as sensitive as molecular testing
methods (McKinney, 2020). Nevertheless, antigen testing could prove to be cheaper and have a
higher throughput (Patel, 2020). The first EUA went to Quidel Corporation‚Äôs Sofia 2 SARS
Antigen FIA (Burton, 2020).
Because of the possibility of false negatives, physicians are told not to rely solely on these
COVID-19 test results alone, but also to evaluate their patients and consider diagnostic tests
such as CT (computed tomography) scans. CT scans of COVID-19 patients often exhibit some
percentage of ground-glass opacity (GGO) patterns (Belfiore et al., 2020; Dai et al., 2020).
GGO‚Äôs are not, however, unique to COVID-19, and physicians should still take a holistic
approach to diagnose COVID-19, i.e., considering patient history or risks of exposure to
COVID-19.
Along with properly testing and diagnosing COVID-19, significant effort has been spent on
developing a vaccine to combat the virus. The first expected COVID-19 vaccine in China was
available for clinical testing by the end of April (Cahill, 2020). Another player in vaccine
development is ‚ÄãInovio Pharmaceuticals, which expected to launch clinical trials in April using
their INO-4800 vaccine, with results anticipated in September of 2020 (Cahill, 2020). Regeneron
is also working diligently to move its clinical trials of REGN3048 and REGN3051 vaccine and
treatment up to early summer(Cahill, 2020). Moderna began testing their mRNA-1273 vaccine
clinically beginning in April; this vaccine in particular is designed to target the Spike (S) protein
of the virus (Cahill, 2020).‚Äã Additionally, an intranasal vaccine is being developed via animal
studies by the biopharmaceutical company Altimmune (Cahill, 2020).
However, vaccines provide no help to those already infected, so significant effort has also been
expended on developing pharmaceuticals to combat COVID-19 in those already infected. A
novel treatment may take a significant amount of time to develop so many efforts have been
focused on drug repurposing. Examples of this include Gilead‚Äôs Remdesivir (GS-5734) a
general antiviral drug formulated to treat Ebola. This drug treated 761 patients with the virus in a
Wuhan hospital (Cairns, 2020) and has performed better than most drugs to date. Another
example is Olumiant, a ‚Äãrh
‚Äã eumatoid arthritis drug which was identified as a possible treatment of
COVID-19 by means of artificial intelligence (Sagonowsky, 2020) . Additionally, Avigan an
influenza antiviral drug has seen promising results and has moved into phase III clinical trials
(Balfour, 2020b; Lewis, 2020). However, some repurposing drug attempts, like that of the
anti-malaria drug hydroxychloroquine, are failing to show efficacy under scientific scrutiny

medRxiv preprint doi: https://doi.org/10.1101/2020.07.24.20161547; this version posted July 27, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

4
(Allassan, 2020; Hopkins, 2020; Sagonowsky, 2020). Efforts to identify a possible treatment
among other experimental drugs are also being conducted. EIDD-2801 is a compound originally
developed for treating influenza. EIDD-2801 has shown to interfere with the virus‚Äô reproduction
cycle and has shown promising results in the animal testing (Sheahan et al., 2020). A similar
story can be told for the compound EDP-1815, which was developed for anti-inflammatory
diseases and is in phase 1b trials for psoriasis (Cotrone, 2020; Verbanas, 2020). EDP-1815 has
had success with COVID-19 thus far and is in phase 2 trials at the time of writing this paper
(Verbanas, 2020). The RECOVERY trial of dexamethasone showed that the drug could reduce
COVID-19 patient death risk by one-third in ventilated patients (from 40% to 28%), and by 1/5 in
other patients receiving oxygen only, from 25 percent to 20 percent. There was no benefit in the
RECOVERY trial to patients who did not need respiratory support (Mahase, 2020).
As these various compounds begin to enter later phase trials, developers must move away from
fit-for-purpose (FFP) formulations and move toward development of a final formulation (Marsac,
2019). Formulation is critical in allowing the compound to scale and become a drug product.
One method to cut down on formulation development time and cost is to begin with
better-informed initial formulations.This paper uses computer population modeling to aid in the
development of a smart formulation from the start, one that obviates the need for extensive
preclinical formulation and toxicology studies, thereby significantly reducing development time.
This study examines the use of such a data-driven approach for a new candidate COVID-19
treatment, BSN389. BSN389 is an FDA designated orphan drug currently in development as an
Ebola treatment (Lodder, 2017). The goal of the present study is to determine the current daily
exposure of the population to beta cyclodextrin (BCD), and then keep the amount of BCD in the
formulation below that level, so drug use does not add significantly to BCD exposure of human
subjects.

Methods
This study is designed to use computer population modeling to reduce the need for extensive
preclinical formulation and toxicology studies, and to thereby speed a candidate COVID-19
therapeutic to the clinic. This study updates a previous study with data collected from the latest
NHANES (Lodder, 2017). The data compilation and statistical methods used are described in
(Cambell, 2020) and summarized below.

NHANES Data Mining
Data from the Centers for Disease Control (CDC) National Health and Nutrition Examination
Survey (NHANES) (ClinicalTrials.gov Identifier: NCT00005154) are combined in this
computational experiment with data on shipments from food ingredient manufacturers to
evaluate exposure of the US population through foods to a possible pharmaceutical formulation
ingredient, beta cyclodextrin (Lodder, 2017). Formulation is indispensable in drug delivery. An

medRxiv preprint doi: https://doi.org/10.1101/2020.07.24.20161547; this version posted July 27, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

5
inferior formulation can render a drug product inefficacious. A considerable amount of preclinical
research must be conducted before a new drug candidate can be evaluated in humans. The
cost of these IND-enabling cGxP studies is usually in the range of $3-$5 million. If a misleading
drug product formulation is tested preclinically, new iterations of the formulation must be tested
again at added cost. BSN389 was devised for treatment of Ebola virus infections. BSN389 is
not particularly soluble in water. Therefore, the objective of formulation is to improve the
solubility and bioavailability of the active pharmaceutical ingredient (API).
Data-driven computational science can help to lessen the expense of preclinical work. In the
absence of extant human exposure data, an array of tests involving acute and chronic
toxicology, cardiovascular, central nervous system, and respiratory safety pharmacology must
be completed in at least two species before FDA will allow experiments in humans.
Nonetheless, for many compounds (such as those originating as natural products) there is a
record of human use. In such situations, computer modeling of a population to determine human
use may be sufficient to allow phase 0-1 studies with a candidate formulation in humans.
The CDC‚Äôs National Health and Nutrition Examination Survey (NHANES) is a group of studies
created to assess the health and nutritional levels of adults and children in the United States.
NHANES is distinctive in that it incorporates both interviews and dietary information with
physical examinations with laboratory results. The NHANES database can be analyzed to
determine the distribution of exposures to a food ingredient, and preliminary human formulation
experiments conducted at exposures less than those to which the US population is normally
exposed through food. These data can be integrated with data extracted from international
ingredient shipments to validate the usage model. This report details the data-driven formulation
investigation process employing a novel COVID-19 treatment candidate that, unlike vaccines,
can be utilized after a patient has been infected with the disease. BSN389‚Äôs mechanism of
action allows it to be potentially employed against all strains of the virus, an attribute that
vaccines might not share.
Consumption data from individual dietary records, detailing food items ingested by each survey
participant, were collated by computer in Matlab and used to generate estimates for the intake
of BCD by the U.S. population as previously described (Lodder, 2017). A more complete
description of the methods appears in

Œ≤-Cyclodextrin Uses in Food and Pharmaceuticals
Cyclodextrins (CDs) can be procured in three common forms: Œ±-cyclodextrin, Œ≤-cyclodextrin and
Œ≥-cyclodextrin, which are called the first generation (or parent) cyclodextrins. These
cyclodextrins comprise six (Œ±), seven (Œ≤) and eight (Œ≥) -(1,4)-linked glycosyl units formed into a
ring. The ring-shaped molecule is hydrophilic on the outer surface (permitting the cyclodextrin
to dissolve in water) and has a nonpolar cavity on the inside, which provides a hydrophobic

medRxiv preprint doi: https://doi.org/10.1101/2020.07.24.20161547; this version posted July 27, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

6
environment. Cyclodextrins are able to organize inclusion complexes with a diverse array of
hydrophobic guest molecules using this hydrophobic cavity. One or two guest molecules can be
entrapped by one, two or three molecules of cyclodextrin.
Because Œ≤ cyclodextrin is used in both food and pharmaceuticals, BCD exposure estimates are
more complicated than estimates made just for food. Manufacturers have to be careful when
adding what is apparently a minor amount of BCD to a product because that trivial mass may be
enough to push a consumer already ingesting BCDs from other sources higher than the
Acceptable Daily Intake (ADI) limit.
Every year cyclodextrins are discussed in numerous scientific research articles and meeting
abstracts. Many of these reports are about drugs and drug-related products. Table 1 provides a
summary of some of the commercially marketed pharmaceuticals formulated with cyclodextrins.
In addition, an abundance of novel inventions continue to incorporate cyclodextrins. CDs are
well understood from a regulatory point of view, and a monograph for BCD appeared decades
ago in both the US Pharmacopoeia/National Formulary and the European Pharmacopoeia (Del
Valle, 2004).
Table 1. Commercially marketed pharmaceuticals formulated with cyclodextrins
throughout the world.

Type

Drug name

Trade
name

Route of
Administration

Country

ùõÇ-Cyclodextrin

Cefotiam hexetil
hydrochloride

Pansporin Oral
T

Japan

ùú∑-Cyclodextrin

Omeprazole

Omebeta

Oral

Europe

Benexate
hydrochloride

Ulgut,
Lonmiel

Oral

Japan

Chlordiazepoxide Transilium Oral

Argentina

Nimesulide

Nimedex

Oral

Europe

Nicotine

Nicorette

Sublingual

Europe

medRxiv preprint doi: https://doi.org/10.1101/2020.07.24.20161547; this version posted July 27, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

7

Sulfobutylether
ùú∑-Cyclodextrin

Carfilzomib

Kyprolis

Intravenous

Europe,
USA

Ziprasidone
Maleate

Geodon,
Zeldox

Intramuscular

Europe,
USA

Aripiprazole

Abilify

Intramuscular

USA,
Japan

Voriconazole

Vfend

Intravenous

Europe,
USA

2-Hydroxypropyl
ùú∑-Cyclodextrin

Itraconazole

Sporanox

Oral, ‚ÄãIntravenous Europe,
USA

Methylated
ùú∑-Cyclodextrin

17ùú∑-Estradiol

Aerodiol

Nasal

Europe

2-Hydroxypropyl
ùõæ-Cyclodextrin

Diclofenac
sodium

Voltaren

Ocular

Europe

Data collected from (Jambhekar and Breen, 2016; Kishore Shete et al., 2017; Loftsson et al., 2014;
Loftsson and Duch√™ne, 2007; Nerurkar and Naringrekar, 2013)

Evaluation of Œ≤-Cyclodextrin Use
An evaluation of the utilization of BCD by the U.S. population through the approved uses of
BCD was conducted. Appraisals of the intake of BCD were calculated using the approved food
uses and maximum use level in conjunction with food consumption data included in the National
Center for Health Statistics‚Äô (NCHS) 2015-2016 National Health and Nutrition Examination
Surveys (NHANES) (USDA, 2012; Bodner-Montville et al, 2006). Estimates of the mean and
90th percentile intakes were obtained for combined representative approved food uses of BCD
(see Appendix for lists of food codes used). The intakes were reported for the following
population groups:
‚Ä¢
‚Ä¢
‚Ä¢

infants, age 0 to 1 year
toddlers, age 1 to 2 years,
children, ages 2 to 5 years,

medRxiv preprint doi: https://doi.org/10.1101/2020.07.24.20161547; this version posted July 27, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

8
‚Ä¢
‚Ä¢
‚Ä¢
‚Ä¢

children, ages 6 to 12 years,
teenagers, ages 13 to 19 years,
adults, ages 20 years and up,
total population (all age groups combined, excluding ages 0-2 years),

Results and Discussion
Food Usage
The individual food uses for BCD are synopsized in Appendix 1. Food codes representative of
each approved use were selected from the Food and Nutrition Database for Dietary Studies
(FNDDS) for the appropriate biennial NHANES survey. In FNDDS, the primary (usually generic)
description of a given food is assigned a unique 8-digit food code (USDA, 2012) that appears in
Appendix 1.

Food Survey Results
The estimated ‚Äúall-user‚Äù total intakes of BCD from all approved food uses of BCD in the U.S. by
population group is summarized in Table 2.
Table 2. Estimated ‚ÄúAll-user‚Äù Daily Intake (EDI) of BCD in Targeted Foods by Population
Group (2015-2016 NHANES Data)

Population
Group

Estimated ‚ÄúAll-user‚Äù Daily Intake (EDI) of BCD in Targeted Foods by Population
Group (2015-2016 NHANES Data)
Mean
Mean
90th %
N
mass
Mean
90th % EDI
EDI
N users population % Users (kg)
EDI (g) EDI (g) (g/kg)
(g/kg)

ages 0-1

175

293

59.73

11.22

0.0019

0.0047

0.0002

0.0004

ages 1-2

191

291

65.64

13.59

0.0029

0.0100

0.0002

0.0007

ages 2-5

555

915

60.66

16.92

0.0029

0.0093

0.0002

0.0005

ages 6-12

948

1505

62.99

36.58

0.0044

0.0150

0.0001

0.0004

ages 13-19

768

1143

67.19

67.35

0.0080

0.0224

0.0001

0.0003

ages 20 and up

4169

5748

72.53

79.95

0.0153

0.0322

0.0002

0.0004

ages 2 and up

6440

9311

69.17

66.96

0.0124

0.0303

0.0002

0.0005

medRxiv preprint doi: https://doi.org/10.1101/2020.07.24.20161547; this version posted July 27, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

9

Figure 1. Estimated Daily Intake of BCD in Targeted Foods by Population Group
(2015-2016 NHANES Data)

Figure 2. Weight-Based Estimated Daily Intake of BCD in Targeted Foods by Population
Group (2015-2016 NHANES Data)

medRxiv preprint doi: https://doi.org/10.1101/2020.07.24.20161547; this version posted July 27, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

10

However, every food category in which BCD is approved for use does not necessarily
incorporate BCD into every product in the category at the maximum approved use level. As a
result, the values in Figure 1, Figure 2, and Table 2 are corrected using the total amount of BCD
consumed in food in the United States during the period of the survey. The correction was
derived from US population numbers and market research on the global Œ≤ cyclodextrin industry
(Global and Chinese Œí Cyclodextrin Industry, 2016).
Table 3. US Population Numbers by Year
(from ‚Äãhttp://www.multpl.com/united-states-population/table‚Äã)
Jul 1, 2016
322.94 million
Jul 1, 2014
317.68 million
Jul 1, 2012
312.86 million
Jul 1, 2010
308.11 million
(The selected years for the US population numbers correspond to the second year of the
biennial NHANES surveys.)
To derive the correction factor the US population number for 2016 was multiplied by the fraction
of people aged two and up in the US consuming the targeted food codes:
322,940,000 persons x 0.6917 = 223,377,598 BCD consumers

medRxiv preprint doi: https://doi.org/10.1101/2020.07.24.20161547; this version posted July 27, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

11
1012 tons of BCD were shipped into the US and presumably consumed in US foods in 2016
(Global and Chinese Œí Cyclodextrin Industry, 2016). This number was converted to grams and
divided by the number of BCD consumers in the United States to give: 1012000000 g /
223377598 consumers = 4.53 g/consumer/yr.
Dividing the grams per consumer per year by 365 gives grams per consumer per day, or
0.0124 g. To derive the correction factor the maximum g/consumer/day for ages 2+ in the
NHANES table is divided by the actual g/day, 2.0237/0.0124 = 163.2. The estimated maximum
exposures provided by the 2015-2016 NHANES were divided by 163.2 to get estimated actual
exposures in Table 2.

Development
Scale-up of a novel pharmaceutical may prove difficult during a pandemic, especially with
common inactive ingredients such as cyclodextrin, which are used in a wide variety of industries
as mentioned (Astray et al., 2009; Hahn, 2020; Loftsson et al., 2014; Loftsson and Duch√™ne,
2007). ùú∑-Cyclodextrin, like many active and inactive pharmaceutical ingredients, is now supplied
through a global supply chain (GSC) system. Cyclodextrin is made in less than 100
manufacturing sites worldwide, with the majority of these manufacturing sites located overseas
in Western Europe and Japan. With a weakened workforce and broken links for importing and
exporting goods during the global pandemic, shortages in pharmaceutical products have been
reported (Hahn, 2020). Additional research will investigate the feasibility of scale-up of a novel
pharmaceutical during periods of material and workforce shortages. This work will construct a
model able to identify and mitigate potential supply chain risks and ultimately allow scale-up to
occur. The model will need to incorporate country-level reserves and trade data similar to that of
the work done by Korniejczuk or Marchand (Korniejczuk, 2019; Marchand et al., 2016).
Additionally, the model should capture the actions and interactions of those that will be
supplying the material and those that would be further harmed by the shifting inventory
adjustments required for producing the new product. This aspect could be feasibly done by
integrating social dilemma models such as in Hauser‚Äôs work (Hauser et al., 2019).

Conclusion
BCD use is increasing in terms of the number of foods approved for BCD incorporation, and in
2016 69.17% of the total U.S. population of 2+ years were established as consumers of BCD
based on the approved food uses. However, the mean intakes of BCD by the 2016 BCD
consumers from all approved food uses were estimated to be 12.4 mg/person/day or 0.2 mg/kg
body weight/day, a slight decrease from 2014 (Lodder, 2017). The heavy consumer (90th
percentile all-user) intakes of BCD from all approved food-uses were estimated to be 30.3
mg/person/day or 0.5 mg/kg body weight/day. The initial human clinical studies of BSN389 for
COVID-19 will use 1.5 Œºg of BCD. This is over a factor of 1,000 smaller than the expected daily

medRxiv preprint doi: https://doi.org/10.1101/2020.07.24.20161547; this version posted July 27, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

12
intake from the food uses, and much less than the amount required to move the average
consumer from the 50th to the 90th percentile of consumption. For these reasons, the use of
BCD in the BSN389 formulation is an negligible inclusion to daily intake and should be safe for
subjects in the COVID-19 clinical trial.

Acknowledgements
The project described was supported by NSF ACI-1053575 allocation number BIO170011 and
the National Center for Research Resources and the National Center for Advancing
Translational Sciences, National Institutes of Health, through Grant UL1TR001998. The content
is solely the responsibility of the authors and does not necessarily represent the official views of
the NIH.

References
Allassan, F., 2020. Fauci : Data is " really quite evident " against hydroxychloroquine for
coronavirus The Italian Embassy and ISSNAF launch a COVID-19 fundraiser World
coronavirus updates Livestream : Axios hosts an event on COVID-19 ‚Äô s impact on
nursing homes Coronavirus. Axios.
Amanat, F., Nguyen, T., Chromikova, V., Strohmeier, S., Stadlbauer, D., Javier, A., Jiang,
K., Asthagiri-Arunkumar, G., Polanco, J., Bermudez-Gonzalez, M., Caplivski, D.,
Cheng, A., Kedzierska, K., Vapalahti, O., Hepojoki, J., Simon, V., Krammer, F., 2020.
A serological assay to detect SARS-CoV-2 seroconversion in humans. medRxiv
2020.03.17.20037713. ‚Äãhttps://doi.org/10.1101/2020.03.17.20037713
Armstrong, D.W., Ward, T.J., Armstrong, R.D., Beesley, T.E., 1986. Separation of drug
stereoisomers by the formation of Œ≤-cyclodextrin inclusion complexes. Sci. AAAS 232,
1132‚Äì1135. ‚Äãhttps://doi.org/10.1126/science.3704640
Bai, N., 2020. The promise and uncertainties of antibody testing for coronavirus 2020.
Balfour, H., 2020a. Remdesivir most promising COVID-19 drug, say researchers. Russell
Publ. Ltd. 44.
Balfour, H., 2020b. Avigan influenza antiviral to enter phase III trials in COVID-19
patients.pdf. Eur. Pharm. Rev.
Belfiore, M.P., Urraro, F., Grassi, R., Giacobbe, G., Patelli, G., Cappabianca, S., Reginelli,
A., 2020. Artificial intelligence to codify lung CT in Covid-19 patients. Radiol. Med.
500‚Äì504. ‚Äãhttps://doi.org/10.1007/s11547-020-01195-x
Billingsley, A., 2020. The Latest in Coronavirus (COVID-19) Testing Methods and
Availability 19, 2019‚Äì2020.
Bodner-Montville, J., Ahuja, J.K.C., Ingwersen, L.A., Haggerty, E.S., Enns, C.W., Perloff,
B.P., 2006. USDA Food and Nutrient Database for Dietary Studies: Released on the
web. J. Food Compos. Anal. 19, 100‚Äì107. ‚Äãhttps://doi.org/10.1016/j.jfca.2006.02.002

medRxiv preprint doi: https://doi.org/10.1101/2020.07.24.20161547; this version posted July 27, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

13
Burton, T.M., 2020. FDA Grants Emergency-Use Status for First Coronavirus Antigen Test
- WSJ.pdf. Dow Jones Co.
Cahill, J., 2020. An update on drugs in dentistry: Part 2. Life Sci. Lead.
Cairns, E., 2020. Covid-19 antibody tests face a very specific problem. Eval. Vantage
2020.
Campbell, Heather R. and Lodder, Robert A., 2020, Methods for Using NHANES for
Exposure Estimates, CIC Pharmaceutical Sciences, 1-13.
https://docs.google.com/document/d/10lkQC7v8mL_YX4bPpRugt_pVkAL2p4ArIN1N
mppQz_w/edit?usp=sharing
Cohut, M., Godfrey, I., 2020. COVID-19 reasons for hope : Vaccine trials take center stage
Biotech experiments with inactivated virus. Med. News Today.
Colchester, M., Roland, D., 2020. U.K. Trials Coronavirus-Immunity Tests for Home Use.
Dow Jones Co.
Cotrone, J., 2020. Evelo Biosciences Reports Further Positive EDP1815 Interim Clinical
Data in Patients with Psoriasis at High Dose in Phase 1b Trial. Bio Sp.
Covid-, F., 2020. How Antibody Testing Can Help Us COVID-19 Not Sure You Have
COVID-19 ? Here Are the Symptoms for How to Prep for the Coronavirus at Home
COVID-19 Can Attack the Heart in Addition to the Lungs What to Know About
COVID-19 and Strokes Can COVID-19 Damage You.
Dai, W.C., Zhang, H.W., Yu, J., Xu, H.J., Chen, H., Luo, S.P., Zhang, H., Liang, L.H., Wu,
X.L., Lei, Y., Lin, F., 2020. CT Imaging and Differential Diagnosis of COVID-19. Can.
Assoc. Radiol. J. 71, 195‚Äì200. ‚Äãhttps://doi.org/10.1177/0846537120913033
Del Valle, E.M.M., 2004. Cyclodextrins and their uses: A review. Process Biochem. 39,
1033‚Äì1046. ‚Äãhttps://doi.org/10.1016/S0032-9592(03)00258-9
FDA, 2020. EUA Authorized Serology Test Performance. FDA.
Fernandez, M., 2020. FDA authorizes two-minute antibody testing kit to detect coronavirus
- Axios.pdf. AXIOS.
Ghose, T., 2020. How are people being infected with COVID-19? Live Sci.
Global and Chinese Beta Cyclodextrin Industry, 2016 Market Research Report, Prof
Research Nov. 2016, n.d.
Gray, L., 2020. COVID-19 coronavirus spike holds infectivity details. Univ. Washingt. Med.
Hale, C., 2020a. U.S. government funds OraSure‚Äôs at-home spit test for coronavirus
infections. Fierce Biotech.
Hale, C., 2020b. NYU study flags false negatives from Abbott‚Äôs portable coronavirus test,
while FDA lists concerns _ FierceBiotech.pdf. Fierce Biotech.
Hale, C., 2020c. EUA Authorized Serology Test Performance. Fierce Biotech.
Hale, C., 2020d. Abbott launches coronavirus antibody lab test, plans to ship 20M per
month this summer _ FierceBiotech.pdf. Fierce Biotech.
Hale, C., 2020e. Current COVID-19 antibody tests aren‚Äôt accurate enough for mass
screening, say Oxford researchers | FierceBiotech. Fierce Biotech.
Haskins, B., 2020. LabCorp Launches New Test for Coronavirus. North Carolina
Biotechnol. Cent.

medRxiv preprint doi: https://doi.org/10.1101/2020.07.24.20161547; this version posted July 27, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

14
Hopkins, J.S., 2020. Antimalaria Drug Doesn‚Äôt Help Treat Covid-19, Large But Inconclusive
Study Finds - WSJ.pdf. Dow Jones Co.
Jambhekar, S.S., Breen, P., 2016. Cyclodextrins in pharmaceutical formulations I:
Structure and physicochemical properties, formation of complexes, and types of
complex. Drug Discov. Today 21, 356‚Äì362.
https://doi.org/10.1016/j.drudis.2015.11.017
Johnson, M., 2020. How FDA Plans to Tackle Coronavirus Serology Tests ‚Ä¶ For Now. 360
Dx.
Kishore Shete, H., Omprakash Pathak, P., Slingh, S., Malhotra, G., 2017. Stable
Carfilzomib Formulation US10 , 098 , 890 B2.
Kobokovich, A., West, R., Grovall, G., 2020a. Molecular-based Tests for COVID-19 How
Do Molecular Tests Detect SARS-CoV-2 ? Common Types of Molecular and Antigen
Tests Being Current Molecular and Antigen Tests with FDA EUA 21202.
Kobokovich, A., West, R., Grovall, G., 2020b. Serology-based tests for COVID-19. Johns
Hopkins Univ. 19‚Äì22.
Koval, J., Ross, D., Dauer, L., 2020. Abbot launches molecular point-of-care test to detect
novel coronavirus in as little as five minutes. Abbott 564, 1‚Äì2.
Lewis, T., 2020. Here‚Äôs What We Know about the Most Touted Drugs Tested for
COVID-19. . Sci. Am.
Lodder, R.A., 2017. Data-Driven Design of an Ebola Therapeutic. Procedia Comput. Sci.
108, 1612‚Äì1621. ‚Äãhttps://doi.org/10.1016/j.procs.2017.05.127
Loftsson, T., Duch√™ne, D., 2007. Cyclodextrins and their pharmaceutical applications. Int.
J. Pharm. 329, 1‚Äì11. ‚Äãhttps://doi.org/10.1016/j.ijpharm.2006.10.044
Loftsson, T., Jarho, P., Masson, M., Javinen, T., 2014. Cyclodextrins in drug delivery.
Expert Opin. Drug Deliv. 2, 335‚Äì351. ‚Äãhttps://doi.org/10.1201/b17271
Mahase, E. Covid-19: Low dose steroid cuts death in ventilated patients by one third, trial
finds BMJ 2020;369:m2422
Marsac, P.J., 2019. Preformulation in Drug Development-Presentation.
McKinney, J., 2020. Coronavirus ( COVID-19 ) Update : FDA Authorizes First Antigen Test
to Help in the Rapid Detection of the Virus that Causes COVID-19 in Patients. FDA.
Nerurkar, M., Naringrekar, H., 2013. ARIPPRAZOLE COMPLEX FORMULATION AND
METHOD Pub . No .: US 2014 / 0332121 A1.
Patel, N. V., 2020. Antigen testing could be a faster , cheaper way to diagnose covid-19
shopping for good. MIT Technol. Rev. 3.
Repici, A., Maselli, R., Colombo, M., Gabbiadini, R., Spadaccini, M., Anderloni, A., Carrara,
S., Fugazza, A., Di Leo, M., Galtieri, P.A., Pellegatta, G., Ferrara, E.C., Azzolini, E.,
Lagioia, M., 2020. Coronavirus (COVID-19) outbreak: what the department of
endoscopy should know. Gastrointest. Endosc. 1‚Äì6.
https://doi.org/10.1016/j.gie.2020.03.019
Sagonowsky, E., 2020. Lilly partners with NIH to test Olumiant in patients hospitalized with
COVID-19 in Minutes Chatting 1 : 1 in Minutes Understanding the Importance of
Crystallization. Fierce Pharma 2020.

medRxiv preprint doi: https://doi.org/10.1101/2020.07.24.20161547; this version posted July 27, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

15
Saplakoglu, Y., 2020. Here‚Äôs why the new coronavirus is so good at infecting human cells.
Live Sci.
Sheahan, T.P., Sims, A.C., Zhou, S., Graham, R.L., Pruijssers, A.J., Agostini, M.L., Leist,
S.R., Sch√§fer, A., Dinnon, K.H., Stevens, L.J., Chappell, J.D., Lu, X., Hughes, T.M.,
George, A.S., Hill, C.S., Montgomery, S.A., Brown, A.J., Bluemling, G.R., Natchus,
M.G., Saindane, M., Kolykhalov, A.A., Painter, G., Harcourt, J., Tamin, A., Thornburg,
N.J., Swanstrom, R., Denison, M.R., Baric, R.S., 2020. An orally bioavailable
broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures
and multiple coronaviruses in mice. Sci. Transl. Med. 12.
https://doi.org/10.1126/scitranslmed.abb5883
Spaulding, E., 2020. Coronavirus ( COVID-19 ) Update : FDA Informs Public About
Possible Accuracy Concerns with Abbott ID NOW Point-of-Care Test. FDA.
Spaulding, E., Mueller, N., 2020. Coronavirus ( COVID-19 ) Update : FDA Authorizes First
Standalone At-Home Sample Collection Kit That Can Be Used With Certain
Authorized Tests. FDA.
Tina, Saey, H., 2020a. Loss of smell and taste may actually be one of the clearest signs of
COVID-19. Sci. News. ‚Äãhttps://doi.org/10.1038/s41591-020-0916-2‚Äã.
Tina, Saey, H., 2020b. Just breathing or talking may be enough to spread COVID-19 after
all. Sci. News.
USDA, 2012. What We Eat In America (WWEIA), NHANES: overview.
Verbanas, P., 2020. Rutgers Leads Clinical Trial of Drug to Prevent Cytokine Storms in
COVID-19 Patients. Rutgers Univ.
Volkin, S., 2020. How long can the virus that causes COVID-19 live on surfaces? Johns
Hopkins Univ. 3910.
Weaver, B.C., 2020. Questions About Accuracy of Coronavirus Tests Sow Worry. Dow
Jones Co. 2‚Äì7.
Woodward, A., Miller, Medaris, A., 2020. Multiple experts say up to 70 % of Americans
could be infected with the coronavirus and 1 million could die if no treatment is found
‚Äî so people over 60 should ‚Äô stay home unless it ‚Äô s critical ‚Äô. New York Times.
Wu, J., Morrow, C., 2020. Emory‚Äôs antibody study sheds light on COVID-19 immunity
30322.
Wu, Y., 2020. Compensation of ACE2 Function for Possible Clinical Management of
2019-nCoV-Induced Acute Lung Injury. Virol. Sin. 12250, 2019‚Äì2021.
https://doi.org/10.1007/s12250-020-00205-6

